Cooper Companies (COO) Price Target Raised to $305.00
Cooper Companies (NYSE:COO) had its target price hoisted by Jefferies Financial Group to $305.00 in a research note issued to investors on Friday morning, The Fly reports. Jefferies Financial Group currently has a buy rating on the medical device company’s stock. Jefferies Financial Group also issued estimates for Cooper Companies’ Q4 2018 earnings at $2.94 EPS, FY2018 earnings at $11.58 EPS, Q1 2019 earnings at $2.68 EPS, Q2 2019 earnings at $2.91 EPS, Q3 2019 earnings at $3.21 EPS, Q4 2019 earnings at $3.10 EPS, FY2019 earnings at $11.90 EPS, FY2020 earnings at $13.50 EPS and FY2021 earnings at $15.05 EPS.
Several other equities research analysts have also issued reports on COO. BMO Capital Markets raised their target price on shares of Cooper Companies from $294.00 to $306.00 and gave the stock an outperform rating in a report on Friday. ValuEngine upgraded shares of Cooper Companies from a hold rating to a buy rating in a report on Thursday, September 27th. Zacks Investment Research restated a hold rating and issued a $285.00 target price on shares of Cooper Companies in a report on Monday, November 12th. Oppenheimer set a $270.00 target price on shares of Cooper Companies and gave the stock a hold rating in a report on Friday, August 31st. Finally, KeyCorp decreased their price objective on shares of Cooper Companies from $298.00 to $296.00 and set an overweight rating for the company in a report on Friday. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $284.50.
Shares of Cooper Companies stock traded down $34.02 during trading on Friday, hitting $243.01. The stock had a trading volume of 1,253,678 shares, compared to its average volume of 333,174. The firm has a market capitalization of $13.61 billion, a PE ratio of 21.13, a price-to-earnings-growth ratio of 2.13 and a beta of 0.77. The company has a current ratio of 2.58, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. Cooper Companies has a 12 month low of $216.47 and a 12 month high of $283.18.
In related news, Director Allan E. Rubenstein sold 1,500 shares of Cooper Companies stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $265.37, for a total transaction of $398,055.00. Following the completion of the sale, the director now owns 3,068 shares in the company, valued at approximately $814,155.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Randal Golden sold 1,731 shares of Cooper Companies stock in a transaction dated Thursday, September 27th. The shares were sold at an average price of $275.86, for a total transaction of $477,513.66. Following the sale, the vice president now owns 1,154 shares of the company’s stock, valued at approximately $318,342.44. The disclosure for this sale can be found here. Insiders have sold a total of 20,691 shares of company stock valued at $5,527,869 in the last quarter. 1.60% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Handelsinvest Investeringsforvaltning increased its position in Cooper Companies by 23.1% during the 3rd quarter. Handelsinvest Investeringsforvaltning now owns 51,696 shares of the medical device company’s stock valued at $14,327,000 after purchasing an additional 9,700 shares during the period. Raymond James Trust N.A. purchased a new position in Cooper Companies during the 3rd quarter valued at about $214,000. Andra AP fonden purchased a new position in Cooper Companies during the 2nd quarter valued at about $2,072,000. We Are One Seven LLC purchased a new position in Cooper Companies during the 3rd quarter valued at about $394,000. Finally, American International Group Inc. increased its position in Cooper Companies by 6.0% during the 3rd quarter. American International Group Inc. now owns 18,156 shares of the medical device company’s stock valued at $5,032,000 after purchasing an additional 1,023 shares during the period.
About Cooper Companies
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
See Also: Treasury Bonds
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.